RPN2 and soft tissue sarcoma: Furthermore, studies of second-line chemotherapy for osteosarcoma have made progress in recent years.25 In phase 2 trials with gemcitabine or docetaxel alone, up to 8% of patients with bone or soft tissue sarcomas showed objective responses.26,27 When gemcitabine was combined with docetaxel in a series of 10 patients with recurrent or progressive osteosarcoma, three patients showed partial responses and one showed stable disease.28 Since silencing of RPN2 could sensitize osteosarcoma to docetaxel, this approach might also be effective for patients with recurrent or progressive osteosarcoma.